Skip to main content

Advertisement

Table 3 Relative risk of selected cancer incidence for female registered nurses according to weighted duration of exposure to antineoplastic agents (method 2), 1974-2000 (N = 56,213)1,2,3,4

From: Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs

Site (ICD-9 code) Weighted duration of exposure5 Observed RR CI (95%) p-value6
All cancers except < 15 days 2905 1.00   0.452
non-melanoma skin 15 to < 60 days 150 1.11 0.94-1.30  
  ≥ 60 days 44 1.00 0.74-1.35  
  top 2 categories combined 194 1.08 0.93-1.25  
Colon (153,159) < 15 days 225 1.00   0.710
  15 to < 60 days 11 1.16 0.63-2.13  
  ≥ 60 days < 3    
  top 2 categories combined 13 0.99 0.56-1.74  
Rectum (154) < 15 days 116 1.00   0.037
  15 to < 60 days 10 1.85 0.96-3.56  
  ≥ 60 days 4 1.93 0.71-5.25  
  top 2 categories combined 14 1.87 1.07-3.29  
Lung (162) < 15 days 202 1.00   0.867
  15 to < 60 days 11 1.24 0.67-2.28  
  ≥ 60 days 3 0.83 0.27-2.61  
  top 2 categories combined 14 1.22 0.65-1.94  
Melanoma (172) < 15 days 191 1.00   0.400
  15 to < 60 days 12 1.28 0.71-2.30  
  ≥ 60 days 3 1.28 0.41-4.02  
  top 2 categories combined 15 1.28 0.75-2.18  
Breast (174) < 15 days 1199 1.00   0.267
  15 to < 60 days 64 1.08 0.84-1.39  
  ≥ 60 days 23 1.23 0.82-1.87  
  top 2 categories combined 87 1.12 0.89-1.39  
Uterus (179-182) < 15 days 290 1.00   0.696
  15 to < 60 days 9 0.72 0.37-1.40  
  ≥ 60 days 7 1.66 0.78-3.53  
  top 2 categories combined 16 0.95 0.57-1.59  
Ovary (183) < 15 days 144 1.00   0.209
  15 to < 60 days 6 0.90 0.40-2.06  
  ≥ 60 days < 3    
  top 2 categories combined 6 0.68 0.30-1.55  
Bladder - including in-situ (188) < 15 days 78 1.00   0.394
  15 to < 60 days 6 2.00 0.86-4.65  
  ≥ 60 days < 3    
  top 2 categories combined 7 1.67 0.76-3.67  
Brain (191-192) < 15 days 43 1.00   0.292
  15 to < 60 days 3 1.76 0.54-5.80  
  ≥ 60 days < 3 1.88 0.26-13.87  
  top 2 categories combined 4 1.79 0.63-5.10  
Thyroid (193) < 15 days 82 1.00   0.408
  15 to < 60 days 4 0.93 0.34-2.56  
  ≥ 60 days     
   < 3    
  top 2 categories combined 4 0.74 0.27-2.05  
Ill-defined (195) < 15 days 81 1.00   0.181
  15 to < 60 days 5 1.33 0.54-3.31  
  ≥ 60 days 3 2.09 0.66-6.65  
  top 2 categories combined 8 1.54 0.74-3.21  
Lymphatic & Hematopoietic < 15 days 219 1.00   0.482
(200-208) 15 to < 60 days 9 0.93 0.47-1.82  
  ≥ 60 days < 3    
  top 2 categories combined 11 0.84 0.46-1.55  
Non-Hodgkin Lymphoma < 15 days 121 1.00   0.643
(200, 202) 15 to < 60 days 6 1.06 0.47-2.43  
  ≥ 60 days < 3 0.49 0.07-3.52  
  top 2 categories combined 7 0.91 0.42-1.96  
Leukemia (204-208) < 15 days 59 1.00   0.930
  15 to < 60 days < 3    
  ≥ 60 days < 3    
  top 2 categories combined 3 0.89 0.27 - 2.88  
  1. 1 Based on Poisson regression using a 10-year lag.
  2. 2 Cancer with an incidence of less than 3 were excluded.
  3. 3 N for top 2 categories of antineoplastic drug exposure = 7,635.
  4. 4 Adjusted for age and calendar year.
  5. 5 A weighted duration of exposure of 15 days is equivalent to full-time work for one year (240 days) at a job considered unlikely to be exposed; a weighted duration of exposure of 60 days is equivalent to full-time work for one year at a job considered possibly exposed.
  6. 6 Significance of the trend, derived from chi-square analysis.